S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 2/26/2024
This infrastructure construction stock: Is it ready to pop?
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 2/26/2024
This infrastructure construction stock: Is it ready to pop?
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 2/26/2024
This infrastructure construction stock: Is it ready to pop?
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 2/26/2024
This infrastructure construction stock: Is it ready to pop?
NASDAQ:HSKA

Heska (HSKA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$119.99
$119.99
50-Day Range
$115.55
$119.99
52-Week Range
$57.83
$120.03
Volume
N/A
Average Volume
241,932 shs
Market Capitalization
$1.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$133.00

HSKA stock logo

About Heska Stock (NASDAQ:HSKA)

Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.


HSKA Stock News Headlines

Why Heska (HSKA) Hit a One-Year High Today
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Why eXp World Holdings Shares Are Rising Thursday
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Why Heska Stock Is On Fire Today
Heska (HSKA) Moves to Buy: Rationale Behind the Upgrade
Heska (HSKA) Moves 9.0% Higher: Will This Strength Last?
Heska Corporation Reports Third Quarter 2022 Results
See More Headlines
Receive HSKA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
2/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
Current Symbol
NASDAQ:HSKA
Employees
808
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$133.00
High Stock Price Target
$150.00
Low Stock Price Target
$120.00
Potential Upside/Downside
+10.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-19,890,000.00
Pretax Margin
-7.91%

Debt

Sales & Book Value

Annual Sales
$257.31 million
Cash Flow
$1.69 per share
Book Value
$39.00 per share

Miscellaneous

Free Float
9,572,000
Market Cap
$1.31 billion
Optionable
Not Optionable
Beta
1.58
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Kevin S. WilsonMr. Kevin S. Wilson (Age 51)
    CEO, Pres & Director
    Comp: $988.17k
  • Ms. Catherine I. Grassman CPAMs. Catherine I. Grassman CPA (Age 47)
    Exec. VP & CFO
    Comp: $536.46k
  • Mr. Christopher D. Sveen (Age 40)
    EVP, Chief Admn. Officer, Gen. Counsel, Corp. Sec. & Pres of Diamond Animal Health
    Comp: $457.89k
  • Mr. Steven M. Eyl (Age 57)
    Exec. VP, Chief Commercial Officer & Pres of scil animal care company
    Comp: $475.28k
  • Ms. Eleanor F. Baker (Age 38)
    Exec. VP, MD & COO of Scil Animal Care Company
    Comp: $467.77k
  • Mr. Jon Aagaard
    Director of Investor Relations
  • Mr. Anthony C. Providenti Jr. (Age 56)
    Exec. VP of Corp. Devel.
  • Dr. Nancy Wisnewski Ph.D. (Age 60)
    Chief Science Advisor to CEO
  • Daniel J. Pollack
    VP of Imaging Operations, Treasurer & Assistant Sec.
  • Cynthia Patterson
    VP of Customer Care














HSKA Stock Analysis - Frequently Asked Questions

Should I buy or sell Heska stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Heska in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HSKA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HSKA, but not buy additional shares or sell existing shares.
View HSKA analyst ratings
or view top-rated stocks.

What is Heska's stock price target for 2024?

2 analysts have issued 12-month price objectives for Heska's stock. Their HSKA share price targets range from $120.00 to $150.00. On average, they anticipate the company's share price to reach $133.00 in the next twelve months. This suggests a possible upside of 10.8% from the stock's current price.
View analysts price targets for HSKA
or view top-rated stocks among Wall Street analysts.

How were Heska's earnings last quarter?

Heska Co. (NASDAQ:HSKA) released its quarterly earnings results on Thursday, November, 4th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.23. The medical research company had revenue of $60.24 million for the quarter, compared to analyst estimates of $63.80 million. Heska had a positive trailing twelve-month return on equity of 0.94% and a negative net margin of 7.86%. The business's quarterly revenue was up 6.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.25) earnings per share.

What is Kevin S. Wilson's approval rating as Heska's CEO?

5 employees have rated Heska Chief Executive Officer Kevin S. Wilson on Glassdoor.com. Kevin S. Wilson has an approval rating of 57% among the company's employees. This puts Kevin S. Wilson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Heska own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK).

This page (NASDAQ:HSKA) was last updated on 2/27/2024 by MarketBeat.com Staff